Since August, mergers and acquisitions in the pharmaceutical industry have been active, including a large number of pharmaceutical companies such as Jianmin Group, Huadong Pharmaceutical, Duorui Pharmaceutical, and China Resources Shuanghe, which have released news of relevant mergers and acquisitions, which has aroused widespread concern
in the industry.
At the end of August, a new pharmaceutical company launched an acquisition!
On August 29, Jiuqiang Bio announced that the company and Xinyu Yuanlang Management Consulting Partnership (hereinafter referred to as "Yuanlang Management") signed an equity transfer agreement on August 29, 2022, and about 131 million yuan was transferred to Fuzhou Maixin Biotechnology Development Co.
, Ltd.
(hereinafter referred to as the "Target Company") held by Yuanlang Management
for 4.
45%.
After the completion of this transaction, the company's shareholding ratio in the target company increased from 95.
55% to 100%, and the target company was changed from a subsidiary of Jiuqiang Biological Holdings to a wholly-owned subsidiary
of Jiuqiang Biologics.
The company said that according to the Rules for the Listing of Stocks on the Growth Enterprise Market of the Shenzhen Stock Exchange, the Measures for the Management of Material Asset Restructuring of Listed Companies and the Articles of Association of Beijing Jiuqiang Biotechnology Co.
, Ltd.
, the transaction does not constitute a related party transaction and does not constitute a material asset restructuring
.
The announcement shows that the target company was established on February 16, 1993, and the business scope licensing project involves the production of Class III medical devices; Class III medical device business; Medical services, etc.
, general items include the production of first-class medical devices; Sale of Class II medical devices; Medical research and experimental development of Class I medical device sales; Medical equipment rental; Machinery and equipment leasing; Sales of pharmaceutical special equipment; Sales of experimental analytical instruments; Manufacture of experimental analytical instruments; Natural science research and experimental development; Software development; Artificial intelligence basic resources and technology platforms, etc
.
Judging from the main financial data of the target company in the past year and the first period, as of July 31, 2022, the target company achieved operating income of 366 million yuan and net profit of 148 million yuan
.
In addition, as of July 31, 2022, the net assets of the target company reached 982 million yuan, an increase
from 835 million yuan as of December 31, 2021.
For the purpose of this transaction, Jiuqiang Bio said that it is conducive to promoting the company's development strategy, standardizing operation and management, improving decision-making efficiency, and is in line with the company's long-term development plan
.
The target company of this transaction is a holding subsidiary of the company, and after the completion of this transaction, the scope of the company's consolidated statements has not changed, and it is not expected to have a material adverse impact on the company's operating conditions and finances, nor will it harm the interests of the company and its shareholders
.
According to the data, Jiuqiang Bio is an enterprise with the main business of research and development, production and sales of biochemical diagnosis, blood coagulation detection, blood group detection and tumor pathology detection, and is one
of the manufacturers of biochemical diagnosis, hemocoagulation detection and tumor immunohistochemical testing products in China.
According to the semi-annual report of 2022, Jiuqiang Bio achieved revenue of 712 million yuan in the first half of the year, a year-on-year decline of 11.
86%; Net profit was 163 million yuan, down 26.
37% year-on-year; Net profit after deduction of non-net profit was 156 million yuan, down 27.
86%
year-on-year.
However, in terms of R&D investment, the company continues to increase its research and development efforts
.
During the reporting period, jiuqiang biological research and development investment was 64.
9045 million yuan, an increase of 15.
78%
over the same period of the previous year.
Among them, the sales expense was 162 million yuan, an increase of 14.
97% year-on-year; Administrative expenses were RMB59.
1486 million, an increase of 5.
98% year-on-year; The reason for the increase in expenses is mainly due
to the increase in labor costs, the increase in amortization expenses for equity incentives, and the increase in promotion efforts.
In terms of stock price performance, the company's stock price performance has not been affected
by the decline in performance.
As of the close of trading on August 30, 2022, Jiuqiang Bio closed at 18.
53 yuan, down 0.
16%, with a turnover rate of 2.
27%, a trading volume of 75,800 lots, and a turnover of 141 million yuan
.
